Evidence map›Paper›PMID 41731545›Full record

ArticleOrphanet journal of rare diseases2026

Educational attainment of individuals with lymphangioleiomyomatosis is a determinant of timely diagnosis and treatment uptake.

Marina K Holz

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Marina K HolzGraduate School of Biomedical Sciences, New York Medical College, Valhalla, NY, 10595, USA. mholz@nymc.edu.ORCID http://orcid.org/0000-0001-5030-7973

Funding

LAM Foundation LAM0161S05
6 · The paper itself

Abstract

backgroundLymphangioleiomyomatosis (LAM) is a rare, progressive lung disease predominantly affecting women. Despite the availability of FDA-approved treatments, mTOR inhibitors like sirolimus or everolimus, significant disparities persist in early diagnosis, treatment utilization, and patient outcomes. The goal of this study is to examine how key socioeconomic factors affect diagnostic delay and treatment uptake in LAM. It was hypothesized that higher educational attainment is associated with earlier diagnosis and greater likelihood of treatment utilization due to its association with health literacy.

resultsTo investigate the impact of socioeconomic factors, we analyzed data from the LAM Patient Research Priorities (LAM-PREP) study, a cross-sectional survey of LAM patients representing ~ 20% of known cases globally. 624 participants completed the survey and 566 provided complete education data and were therefore included in analyses. Multiple regression and logistic regression analyses were performed to examine the associations between educational attainment and diagnostic timing, as well as treatment utilization, controlling for age and disease severity. Among 566 patients with complete educational data, there was a 10-year average delay between self-reported symptom onset (mean age 25.0 ± 12.7 years) and diagnosis (mean age 35.1 ± 13.5 years). Educational attainment emerged as a significant predictor of diagnostic delay. Patients with bachelor’s degrees were diagnosed 4.7 years earlier than those without a bachelor’s degree (95% CI: -7.4 to -2.0, p = 0.001). Only 53% of patients reported using mTOR inhibitors. Educational attainment was a significant predictor of treatment utilization, with patients holding a bachelor’s degree having 1.75 times higher adjusted odds of using mTOR inhibitors (AOR 1.75, 95% CI: 1.13–2.73, p = 0.013), and those with graduate degrees having 2.21 times higher odds (AOR 2.21, 95% CI: 1.41–3.45, p = 0.001).

conclusionsEducational attainment was significantly associated with both the timing of diagnosis and the likelihood of treatment uptake in LAM patients. These findings highlight the need for targeted interventions to address healthcare disparities in LAM care.

Indexed as

LymphangioleiomyomatosisAdolescentAdultCross-Sectional StudiesEducational StatusEverolimusFemaleHumansMaleMiddle AgedSocioeconomic FactorsTreatment DelayYoung AdultEverolimusEducationLymphangioleiomyomatosis (LAM)Patient outcomesRare diseasesTuberous Sclerosis Complex (TSC)

Identifiers

PMID41731545
PMCPMC13032650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.